Suppl. Table S1. Baseline characteristics of the study population

Variable	n = 74	POA < 14.9 µmol/l n = 37	POA ≥ 14.9 µmol/l n = 37	*P* Value
Age (years)	65.6 (6.8)	66.4 (6.0)	64.8 (7.6)	0.30
Female gender, n (%)	26 (35.1)	14 (37.8)	12 (32.4)	0.63
Hypertension, n (%)	72 (97.3)	35 (94.6)	37 (100.0)	0.15
Hyperlipidemia, n (%)	50 (67.6)	22 (59.5)	28 (75.7)	0.13
Metabolic syndrome, n (%)	74 (100.0)	37 (100.0)	37 (100.0)	1.00
Obesity, n (%)	49 (66.2)	20 (54.1)	29 (78.4)	**0.03**
Waist circumference (cm)	106.5 (9.4)	105.7 (10.3)	107.2 (8.5)	0.53
Body mass index, kg/m2	31.2 (3.6)	30.8 (3.9)	31.6 (30.1)	0.34
Body fat (%)	34.1 (8.6)	34.0 (7.6)	34.2 (9.5)	0.93
Visceral fat (%)	16.0 (4.7)	16.0 (4.2)	16.0 (5.1)	1.00
Total body water (%)	47.6 (44.2; 49.3)	47.5 (44.4; 49.4)	47.9 (43.9; 49.3)	1.00
Muscle mass (kg)	55.2 (10.4)	54.0 (10.9)	56.1 (10.2)	0.48
Medical history				
T2D duration (years)	10 (6; 15)	11 (8; 20)	8 (5; 10)	**0.01**

CAD, n (%)	74 (100.0)	37 (100.0)	37 (100.0)	1.00
PAD, n (%)	26 (35.1)	12 (32.4)	14 (37.8)	0.63
Previous MI, n (%)	28 (37.8)	14 (37.8)	14 (37.8)	1.00
Previous PCI, n (%)	47 (65.5)	23 (62.2)	24 (64.9)	0.81
Treatment				
Aspirin, n (%)	74 (100.0)	37 (100.0)	37 (100.0)	1.00
Clopidogrel, n (%)	33 (44.5)	15 (40.5)	18(48.7)	0.48
Beta blocker, n (%)	61 (82.4)	31 (83.8)	30 (81.1)	0.76
ACE inhibitor or ARB, n (%)	67 (90.5)	35 (94.6)	35 (86.5)	0.23
Nitrate long acting, n (%)	11 (14.9)	7 (18.9)	4 (10.8)	0.33
Calcium antagonist, n (%)	32 (43.2)	18 (48.7)	14 (37.8)	0.35
Diuretic, n (%)	40 (54.1)	22 (59.5)	18 (48.7)	0.35
Statin, n (%)	68 (91.9)	35 (94.6)	35 (89.2)	0.39
Fibrate, n (%)	1 (1.4)	0	1 (2.7)	0.31
Metformin, n (%)	49 (66.2)	25 (67.6)	24 (64.9)	0.80
Sulfonylurea, n (%)	31 (41.9)	18 (48.7)	13 (35.1)	0.24
Acarbose, n (%)	3 (4.1)	2 (5.4)	1 (2.7)	0.55
DPP-IV inhibitor, n (%)	1 (1.4)	1 (2.7)	0	0.31
Insulin, n (%)	32 (43.2)	18 (48.7)	14 (37.8)	0.35
Proton pump inhibitor, n (%)	22 (29.7)	10 (27.0)	12 (32.4)	0.61

Data are given as number (percentage) for categorical variables and mean (standard deviation) or median (IQR) for continuous variables.

Abbreviations: ACE, angiotensin-converting enzyme; ARB , angiotensin II receptor blocker; CAD, coronary artery disease; DPP-IV, dipeptidyl peptidase-IV; MI, myocardial infarction;

PAD, peripheral artery disease; PCI, percutaneous coronary intervention; POA, *cis*-palmitoleic acid; T2D, type 2 diabetes.

Suppl. Table S2. Significant Spearman's Rho correlation coefficients between serum phospholipid *cis*-palmitoleic acid (µmol/l) and selected variables

Variable	Correlation coefficient (Rho)	*P* Value
Obesity	0.24	0.04
T2D duration (years)	- 0.29	0.02
cis-C16:1n-7/C16:0 index	0.90	< 0.001
C18:1n-9/C18:0 index	0.43	< 0.001
TC (mmol/L)	0.25	0.03
LDL-C (mmol/L)	0.24	0.04
Tg (mmol/L)	0.29	0.01
ox-LDL (ng/mL)	- 0.29	0.02
Insulin (µIU/mL)	0.26	0.03
Adiponectin (ng/mL)	- 0.27	0.02

Abbreviations: LDL-C, low-density lipoprotein cholesterol; ox-LDL, oxidized low-density lipoprotein; T2D, type 2 diabetes; TC, total cholesterol; Tg, triglycerides.